Lactobacillus plantarum – LP01 (LMG P-21021)

    Gastroenterology strain | Constipation – Antipathogenic activity

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    1) 10 billion CFU

    FUNCTIONALITY
    Constipation • Intestinal transit • Leaky gut • Inhibition of E. coli

    Scientific support

    Human clinical trials
    Del Piano M. et al. The use of probiotics in the treatment of constipation in the elderly. CIBUS, 2005; 1(1):23-30.

    In vitro studies
    a) Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
    b) Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice. J Clin Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008.
    c) Rossi M. et al. Fermentation of fructooligosaccharides and inulin by Bifidobacteria: a comparative study of pure and fecal cultures (BA02). Applied and Environmental Microbiology, 2005;71(10):6150-6158.

    Further internal data on anti-inflammatory activity and intestinal barrier are available upon request


    Gastroenterology blend | IBS – Constipation

    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Bifidobacterium breve – BR03 (DSM 16604)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    1) 5 billion CFU + 5 billion CFU
    2,4) 5 billion CFU / strain (uncoated form) vs. 1 billion cells/strain (microencapsulated form)
    3) 2.5 billion CFU + 2.5 billion CFU • 5) 10 billion CFU

    FUNCTIONALITY
    IBS • Constipation • Intestinal transit • Reduction of gastro-intestinal discomfort • Reduction of inflammation • Inhibition of E. coli, including toxinogenic O157:H7

    Scientific support

    Human clinical trials
    Saggioro A. Probiotics in the treatment of Irritable Bowel Syndrome. J Clin Gastroenterol, 2004; 38(8): S104-106.

    Internal data in vitro on gut permeability and anti-inflammatory activity available upon request.

    In vitro study

    Amoruso A. et al. (2019) A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus Plantarum LP01 (LMG P-21021). J Prob Health. 7:214.


    Gastroenterology blend | IBS

    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactobacillus acidophilus – LA02 (DSM 21717)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    5 billion CFU + 5 billion CFU

    FUNCTIONALITY
    IBS • Reduction of gastro-intestinal discomfort • Reduction of inflammation

    Scientific support

    Human clinical trial
    Saggioro A. Probiotics in the treatment of Irritable Bowel Syndrome. J Clin Gastroenterol, 2004; 38(8): S104-106.

    In vitro study
    Nicola S. et al. Immunomodulation properties of Lactobacillus plantarum LP01 (LMG P-21021) and Lactobacillus acidophilus LA02 (DSM 21717) blend.

    Internal data in vitro on gut permeability and anti-inflammatory activity available upon request.


    Gastroenterology blend | Gastric barrier function – Halitosis

    • Lactobacillus rhamnosus – LR06 (DSM 21981)
    • Lactobacillus pentosus – LPS01 (DSM 21980)
    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactobacillus delbrueckii subsp. delbrueckii – LDD01 (DSM 22106)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    1,2) LR06 3 billion CFU + LPS01 3 billion CFU + LP01 3 billion CFU + LDD01 1 billion CFU 500 million CFU
    3) 1.5 billion CFU per strain

    FUNCTIONALITY
    Gastric barrier function • Improvement of the incidence and severity of bad breath (halitosis)

    Scientific support

    Human clinical trials
    1) Del Piano M. et al. The Innovative Potential of Lactobacillus rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarumLP01 and Lactobacillus delbrueckii subsp. delbrueckii LDD01 to Restore the Gastric
    Barrier Effect” in Patients Chronically Treated with PPIs – a Pilot Study. J Clin Gastroenterol 2010;46:S18-S26.
    2) Del Piano M. et al. Correlation Between Chronic Treatment With Proton Pump Inhibitors (PPIs) and Bacterial Overgrowth in the Stomach – Any Possible Beneficial Role for Selected Lactobacilli? J Clin Gastroenterol
    2014;48:S40-S46.
    3) Del Piano M. et al. Correlation Between Specific Bacterial Groups in the Oral Cavity and the Severity of Halitosis: any Possible Beneficial Role for Selected Lactobacilli? J Gastroint Dig Syst, 2014; 4:197.

    In vitro studies
    a) Mogna L. et al. In Vitro Inhibition of Klebsiella pneumoniae by Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM 22106): An Innovative Strategy to Possibly Counteract Such Infections in Humans? J Clin
    Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S136-S139.
    b) Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different


    Gastroenterology blend | IBD – abdominal surgery – bowel preparation

    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactococcus lactis – LLC02 (DSM 29536)
    • Lactobacillus delbrueckii subsp. delbrueckii – LDD01 (DSM 22106)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    LP01: 1 billion cells. LLC02 800 million cells. LDD01 200 million cells

    FUNCTIONALITY
    Opposing dysbiosis and improving symptoms such as abdominal pain and bloating in patients with Inflammatory bowel diseases, in patients having undergone abdominal surgery and in patients after colonoscopy

    Scientific support

    Human clinical trials
    1) Bonavina L, Arini A, Ficano L, Iannuzziello D, Pasquale L, Aragona SE, Ciprandi G, On Digestive Disorders ISG. Abincol® (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01), an oral nutraceutical, pragmatic use in patients with chronic intestinal disorders. Acta Biomed. 2019 Jul 10;90(7-S):8-12.
    2) Bonavina L, Arini A, Ficano L, Iannuzziello D, Pasquale L, Aragona SE, Ciprandi G, On Digestive Disorders ISG. Post-surgical intestinal dysbiosis: use of an innovative mixture (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01). Acta Biomed. 2019 Jul 10;90(7-S):18-23.
    3) Bonavina L, Ariani A, Ficano L, Iannuzziello D, Pasquale L, Aragona SE, Drago L, Ciprandi G, On Digestive Disorders ISG. Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, and Lactobacillus delbrueckii LDD01) in patients undergoing bowel preparation. Acta Biomed. 2019 Jul 10;90(7-S):13-17.

    In vitro studies
    a) Mogna L. et al. In Vitro Inhibition of Klebsiella pneumoniae by Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM 22106): An Innovative Strategy to Possibly Counteract Such Infections in Humans? J Clin
    Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S136-S139.
    b) Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J Clin Gastroenterol. 2012;46 Suppl.S29-32.


    Immunology blend | Immune stimulation

    • Lactobacillus rhamnosus – LR04 (DSM 16605)
    • Lactobacillus rhamnosus – LR05 (DSM 19739)
    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactobacillus plantarum – LP02 (LMG P-21020)
    • Bifidobacterium animalis subsp. lactis – BS01 (LMG P-21384)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    2.5 billion CFU + 2.5 billion CFU + 2.5 billion CFU + 2.5 billion CFU + 5 billion CFU + FOS or GOS

    FUNCTIONALITY
    Reinforcement of the natural defences • Reduction of the intestinal discomfort • Rebalance of the intestinal microbiota

    Scientific support

    Human clinical trial
    1) Pregliasco F. et al. A New Chance of Preventing Winter Diseases by the Administration of Symbiotic Formulations. Journal of Clinical Gastroenterology, 2008; 42(2): 224-233.
    2) Belcaro G. et al. Prevention of flu episodes with colostrum and Bifivir compared with vaccination: an epidemiological, registry study. Panminerva Medica 2010;52:269-75.

    In vitro study
    Mogna L. et al. Micronized Cells of the Probiotic Strain Bifidobacterium lactis BS01 Activate Monocyte Polarization: A New Approach. J Clin Gastroenterol. 2018;52:S57-S61.

    + Internal data on immune stimulation and anti-pathogen activity available upon request for certain strains


    Immunology blend | Allergic rhinitis

    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactobacillus paracasei – LPC00 (LMG P-21380)

    Characteristics

    FUNCTIONALITY
    1 billion cells each strain + 2,5 g FOS

    FUNCTIONALITY
    Allergic rhinitis

    Scientific support

    Clinical studies and review
    a) Manzotti G. et al. Multi-strain Symbiotic Preparations as a Novel Adjuvant Approach to Allergic Rhinitis. Journal of Contemporary Immunology, Vol. 1 No.2 pp. 67-80, 2014.
    b) Fassio F. House dust mite‑related respiratory allergies and probiotics: a narrative review. Clin Mol Allergy, 2018,16:15.

    + Internal data on immunomodulation available upon request


    Healthy aging strain | Antioxidant

    Characteristics

    FUNCTIONALITY
    Antioxidant activity • Reduced glutathione (GSH) and superoxide dismutase (SOD) production

    Scientific support

    Internal in vitro data available upon request on above-mentioned functions and strains


    Gynecology blend | Bacterial Vaginosis

    • Lactobacillus fermentum – LF15 (DSM 26955)
    • Lactobacillus plantarum – LP01 (LMG P-21021)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    400 million CFU/strain/tablet + Tara gum + FOS + Arabinogalactan

    FUNCTIONALITY
    Vaginal health • Inhibition of Gardnerella vaginalis • Counteraction of Bacterial Vaginosis (BV)

    Scientific support

    Human clinical trial
    Vicariotto F. et al. Effectiveness of the two microorganisms L. fermentum LF15 and L. plantarum LP01, formulated in slow release vaginal tablets, in women affected by Bacterial Vaginosis: a pilot study. J Clin Gastroenterol. 2014; 48 Suppl:S106-112.


    Urology strain | Cystitis

    Characteristics

    FUNCTIONALITY
    Cystitis • Inhibition of E. coli

    Scientific support

    In vitro studies
    Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains (LP01, LP02, LR04, LR06, LPS01, LDD01, BR03, B632). J Clin Gastroenterol. 2012; 46 Suppl:S29-32.

    + Internal data on anti-inflammatory and anti-oxidant properties available upon request for some of these strains


    Urology strain | Kidney stones – Prostate health

    Characteristics

    FUNCTIONALITY
    Oxalate degradation • Reduction of intestinal inflammation • Potential reduction of kidney stones incidence

    Scientific support

    In vitro studies
    Mogna L. et al. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? (LPC09, LA02, LP01, LRE02, BR03, BL03) J Clin Gastroenterol. 2014; 48 Suppl:S91-95.

    + Internal data on anti-inflammatory and anti-oxidant properties available upon request on certain strains

    Clinical studies on-going on LP01+LPC09+Bb1 and other actives in prostate health

    Clinical study

    Chiancone F, Carrino M, Meccariello C, Pucci L, Fedelini M, Fedelini P. The Use of a Combination of Vaccinium Macracarpon, Lycium barbarum L. and Probiotics (Bifiprost®) for the Prevention of Chronic Bacterial Prostatitis: A Double-Blind Randomized Study. Urol Int. 2019; 103(4):423-426. doi: 10.1159/000502765.


    Urology blend | Cystitis – Kidney stones – Prostate health

    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactobacillus paracasei – LPC09 (DSM 24243)

    Characteristics

    FUNCTIONALITY
    1) LP01 2.5 billion + LPC09 1 billion

    FUNCTIONALITY
    Cystitis • Inhibition of E. coli • Metabolization of oxalates, prevention of kidney stones

    Scientific support

    Clinical study
    Vicariotto F. Effectiveness of An Association of a Cranberry Dry Extract, D-Mannose, and the 2 Microorganisms Lactobacillus plantarum LP01 and Lactobacillus paracasei LPC09 in Women Affected by Cystitis. Journal of Clin Gastroenterol 2014;48:S96-S101.

    In vitro studies
    a) Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
    b) Mogna L. et al. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? J Clin Gastroenterol. 2014; 48 Suppl:S91-95.

    + Internal data on anti-inflammatory and anti-oxidant properties available upon request


    Gut-brain strain | Parkinson

    Scientific support

    Luca Magistrelli et al. Probiotics May Have Beneficial Effects in Parkinson’s Disease: In vitro Evidence. Front. Immunol., 07 May 2019


    Gut-brain blend | Mood and sleep quality

    • Bifidobacterium longum – 04 (DSM 23233)
    • Lactobacillus fermentum – LF16 (DSM 26856)
    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactobacillus rhamnosus – LR06 (DSM 21981)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    1 billion cfu/afu per strain

    FUNCTIONALITY
    Improvement of the quality of sleep • Reduction of fatigue and anger • Improvement of mood • Inhibition of E. coli and Candida

    Scientific support

    Human clinical trial
    Marotta A. et al., Effects of Probiotics on Cognitive Reactivity, Mood, and Sleep Quality, 2019 Frontiers in Psychiatry.


    Gut-brain blend | ALS

    • Lactobacillus fermentum – LF10 (DSM 19187)
    • Lactobacillus delbrueckii subsp. delbrueckii – LDD01 (DSM 22106)
    • Lactobacillus plantarum – LP01 (LMG P-21021)
    • Lactobacillus salivarius – LS03 (DSM 22776)

    Characteristics

    DAILY DOSAGE IN CLINICAL STUDY
    LF10 4 billion cfu + LDD01 2 billion cfu + LP01 2 billion cfu + LS03 2 billion cfu

    Scientific support

    Human clinical trial
    Mazzini L. et al. Potential Role of Gut Microbiota in ALS Pathogenesis and Possible Novel Therapeutic Strategies. J Clin Gastroenterol, Vol 00, N 00, 2018.
    Clinical studies on-going